That's an excellent question. I don't have all of the answers, but I know that some of the top lawyers in this country are working on it, and some within our projects. Each of our projects—and this will be true for the 17 projects we're going to announce soon in the personalized health competition—has integrated into it sub-projects that are to do with the ethical, legal, and social issues related to some of this new information we're discovering.
Al mentioned a project on rare diseases that Canada is actually leading the world on in this field. When we sequence people's genomes, families' genomes, with these rare genetic disorders, we're very successful in finding the gene that's causing that particular anomaly. But we're also successful at finding a whole host of other so-called incidental findings. We then have to decide what we should do. Are they actionable? Are they not actionable? Are they important enough to share with the family? Are they not? What's the legal architecture around that? What should we do about it? Those types of questions are being researched by social scientists and humanists within each of our projects.
With regard to this question, I know the Privacy Commissioner of Canada is looking at the particular point that you're driving. I think they've either just published or are just about to publish on some of those concerns. They've been working with the insurance industry on that very topic. I think we will have answers; I don't think we have all of the answers now.